Skip to main content

Table 1 Effect of SGLT2 inhibitors combined with ACEI/ARBs

From: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease

Study

Participants

Intervention

Duration (weeks)

Difference amongst groups (95% CI)

â–³HbA1c (%)

â–³FPG (mmol/L)

â–³SBP (mmHg)

â–³Body weight (kg)

â–³eGFR (mL/min/1.73 m2)

â–³UACR

△Serum uric acid (μmol/L)

â–³Albuminuria

Heerspink [49]

A: n = 167

B: n = 189

A: DAPA 10 mg + ACEI/ARB

B: ACEI/ARB + PBO

12

A–B: −0.5% (−0.7, −0.3)

NR

A–B: −3.5 (−5.9, −1.0)

A âˆ’ B: −0.76 (−1.27, −0.26)

A–B: −2.80 (−5.43, −0.16)

A–B: −23.5% (−37.6, −6.3)

NR

A–B: −33.2% (−45.4, −18.2)

Weber [50]

A: n = 302

B: n = 311

A: DAPA 10 mg + ACEI/ARB

B: ACEI/ARB + PBO

12

A–B: −0.49 (−0.59, −0.33)

A–B: (−0.69 vs 0.38)

A–B: −3.1 (−4.9, −1.2)

A–B: (−1.0 vs −0.3)

NS

NR

A–B: (−17.84 vs 5.95)

NR

Weber [51]

A: n = 225

B: n = 224

A: DAPA 10 mg + ACEI/ARB

B: ACEI/ARB + PBO

12

A–B: −0.61% (−0.76, −0.46)

A–B: −1.2 (−1.7, −0.8)

A–B: −4.28 (−6.54, −2.02)

A–B: −0·85 (−1.39, −0.31)

NS

NS

A–B: −23.67 (−33.70, −13.64)

NR

Sha [52]

A: n = 18

B: n = 18

A: CANA 300 mg + ACEI/ARB + MET

B: ACEI/ARB + PBO + MET

12

A–B: −0.6% (−0.9, −0.3)

A–B: −1.6 (−2.3, −0.9)

A–B: −13.3 (−21.2, −5.3) (supine SBP)

A–B: −16.2 (−24.9, −7.5) (standing SBP)

A–B: −3.5 (−4.2, −2.7)

A–B: −4.0 (−8.7, 0.7)

NR

NR

NR

  1. Data reported as placebo-adjusted difference (95% CI) or adjusted mean change from baseline (A group vs B group)
  2. SGLT2 Sodium–glucose co-transporter 2, ACEI/ARBs angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, 95% CI 95% confidence interval, HbA1c glycated haemoglobin, FPG fasting plasma glucose, SBP systolic blood pressure, eGFR estimated glomerular filtration rate, UACR urinary albumin creatinine ratio, DNPA dapagliflozin, PBO placebo, NR not reported/retrievable, vs versus, NS not-significant, CANA canagliflozin, MET metformin